Company intelligence / Profile preview

SirnaMed

Gaithersburg, Maryland, USA

Ownership: Private
Development stage: Other

Overview

SirnaMed is a biotechnology company focused on the development of RNA interference (RNAi) therapeutics using a proprietary polypeptide nanoparticle (PNP) delivery platform. The company's technology is designed to overcome the challenges of delivering small interfering RNA (siRNA) to target tissues, particularly for skin-related conditions and oncology. SirnaMed's lead programs target fibrotic skin conditions such as hypertrophic scars and keloids by silencing genes involved in the TGF-beta pathway. Additionally, the company is exploring the application of its delivery system for systemic administration in cancer treatment.

Therapeutic areas: OncologyDermatology
Modalities: RNA therapySmall interfering RNANanoparticle
Industry: Biotech

Drug pipeline

3 assets

SMT003

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on SirnaMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SirnaMed.

Explore the full profile